Pathway-Specific Dopamine Abnormalities in Schizophrenia

Biological Psychiatry

Volumn 81, Issue 1, 2017, Pages 31-42

  Weinstein, Jodi J ^a,b   Chohan, Muhammad O ^b   Slifstein, Mark ^a,b   Kegeles, Lawrence S ^a,b   Moore, Holly ^a,b   Abi Dargham, Anissa ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Cortex; Dopamine; Neuroanatomy; PET imaging; Schizophrenia; Striatum

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER;

BRAIN MAPPING; BRAIN REGION; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; HUMAN; INNERVATION; MESENCEPHALON; MOLECULAR IMAGING; NERVE PROJECTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ANIMAL; BRAIN; CAUDATE NUCLEUS; METABOLISM; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SYNAPSE;

ANIMALS; BRAIN; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; NEURAL PATHWAYS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SYNAPSES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84971325767     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.03.2104     Document Type: Review

References (129)

1. 1 Rossum, V., The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160 (1966), 492–494.
2. 2 Carlsson, A., Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135 (1978), 165–173.
3. 3 Seeman, P., Lee, T., Chau-Wong, M., Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (1976), 717–719.
4. 4 Lieberman, J.A., Kane, J.M., Alvir, J., Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91 (1987), 415–433.
5. 5 Weinberger, D.R., Berman, K.F., Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 14 (1988), 157–168.
6. 6 Davis, K.L., Kahn, R.S., Ko, G., Davidson, M., Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148 (1991), 1474–1486.
7. 7 Yung, A.R., McGorry, P.D., McFarlane, C.A., Jackson, H.J., Patton, G.C., Rakkar, A., Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 22 (1996), 283–303.
8. 8 Yung, A.R., Phillips, L.J., McGorry, P.D., McFarlane, C.A., Francey, S., Harrigan, S., et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 172 (1998), 14–20.
9. 9 Howes, O.D., Montgomery, A.J., Asselin, M.C., Murray, R.M., Valli, I., Tabraham, P., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66 (2009), 13–20.
10. 10 Suridjan, I., Rusjan, P., Addington, J., Wilson, A.A., Houle, S., Mizrahi, R., Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci 38 (2013), 98–106.
11. 11 Mizrahi, R., Kenk, M., Suridjan, I., Boileau, I., George, T.P., McKenzie, K., et al. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39 (2014), 1479–1489.
12. 12 Adler, C.M., Elman, I., Weisenfeld, N., Kestler, L., Pickar, D., Breier, A., Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacology 22 (2000), 545–550.
13. 13 Pruessner, J.C., Champagne, F., Meaney, M.J., Dagher, A., Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C]raclopride. J Neurosci 24 (2004), 2825–2831.
14. 14 Mizrahi, R., Addington, J., Rusjan, P.M., Suridjan, I., Ng, A., Boileau, I., et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 71 (2012), 561–567.
15. 15 Soliman, A., O'Driscoll, G.A., Pruessner, J., Holahan, A.L., Boileau, I., Gagnon, D., et al. Stress-induced dopamine release in humans at risk of psychosis: A [11C]raclopride PET study. Neuropsychopharmacology 33 (2008), 2033–2041.
16. 16 Slifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J.L., Narendran, R., Gil, R., et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study. JAMA. Psychiatry 72 (2015), 316–324.
17. 17 Innis, R.B., Cunningham, V.J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R.N., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27 (2007), 1533–1539.
18. 18 Slifstein, M., Laruelle, M., Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 28 (2001), 595–608.
19. 19 Slifstein, M., Hwang, D.-R., Huang, Y., Guo, N., Sudo, Y., Narendran, R., et al. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology 175 (2004), 274–286.
20. 20 Mukherjee, J., Yang, Z.Y., Das, M.K., Brown, T., Fluorinated benzamide neuroleptics—III. development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22 (1995), 283–296.
21. 21 Halldin, C., Farde, L., Hogberg, T., Mohell, N., Hall, H., Suhara, T., et al. Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36 (1995), 1275–1281.
22. 22 Kessler, R.M., Mason, N.S., Votaw, J.R., De Paulis, T., Clanton, J.A., Ansari, M.S., et al. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 223 (1992), 105–107.
23. 23 Narendran, R., Slifstein, M., Guillin, O., Hwang, Y.Y., Hwang, D.R., Scher, E., et al. The dopamine (D-2/3) receptor agonist positron emission tomography radiotracer [C-11)-(+)-PHNO is a D-3 receptor preferring agonist in vivo. Synapse 60 (2006), 485–495.
24. 24 Rabiner, E., Slifstein, M., Nobrega, J., Plisson, C., Huiban, M., Raymond, R., et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)PHNO: Studies in non-hman primates and transgenic mice. Synapse 63 (2009), 782–793.
25. 25 Wilson, A.A., McCormick, P., Kapur, S., Willeit, M., Garcia, A., Hussey, D., et al. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48 (2005), 4153–4160.
26. 26 Abi-Dargham, A., Martinez, D., Mawlawi, O., Simpson, N., Hwang, D.R., Slifstein, M., et al. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: Validation and reproducibility. J Cereb Blood Flow Metab 20 (2000), 225–243.
27. 27 Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 (1997), 634–636.
28. 28 Sesack, S.R., Synaptology of dopamine neurons. Di Chiara, G., (eds.) Dopamine in the CNS, 2002, Springer-Verlag, Berlin, 63–120.
29. 29 Egerton, A., Mehta, M.A., Montgomery, A.J., Lappin, J.M., Howes, O.D., Reeves, S.J., et al. The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neurosci Biobehav Rev 33 (2009), 1109–1132.
30. 30 Sesack, S.R., Aoki, C., Pickel, V.M., Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 14 (1994), 88–106.
31. 31 Hersch, S.M., Ciliax, B.J., Gutekunst, C.A., Rees, H.D., Heilman, C.J., Yung, K.K., et al. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 15 (1995), 5222–5237.
32. 32 Yung, K.K., Bolam, J.P., Smith, A.D., Hersch, S.M., Ciliax, B.J., Levey, A.I., Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy. Neuroscience 65 (1995), 709–730.
33. 33 Laruelle, M., Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20 (2000), 423–451.
34. 34 Cumming, P., Gjedde, A., Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29 (1998), 37–61.
35. 35 Kumakura, Y., Vernaleken, I., Grunder, G., Bartenstein, P., Gjedde, A., Cumming, P., PET studies of net blood-brain clearance of FDOPA to human brain: Age-dependent decline of [18F]fluorodopamine storage capacity. J Cereb Blood Flow Metab 25 (2005), 807–819.
36. 36 Sossi, V., Doudet, D., Holden, J., A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 21 (2001), 469–476.
37. 37 Cropley, V.L., Fujita, M., Bara-Jimenez, W., Brown, A.K., Zhang, X.Y., Sangare, J., et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 163 (2008), 171–182.
38. 38 Kish, S.J., Robitaille, Y., el-Awar, M., Clark, B., Schut, L., Ball, M.J., et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 42 (1992), 1573–1577.
39. 39 Laruelle, M., Wallace, E., Seibyl, J.P., Baldwin, R.M., Zea-Ponce, Y., Zoghbi, S.S., et al. Graphical, kinetic and equilibrium analysis of [123-I]b-CIT in vivo binding to dopamine transporters in healthy subjects. J Cereb Blood Flow Metab 14 (1994), 982–994.
40. 40 Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 91 (1994), 11651–11654.
41. 41 Hietala, J., Syvalahti, E., Vuorio, K., Rakkolainen, V., Bergman, J., Haaparanta, M., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346 (1995), 1130–1131.
42. 42 Hietala, J., Syvalahti, E., Vilkman, H., Vuorio, K., Rakkolainen, V., Bergman, J., et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35 (1999), 41–50.
43. 43 Meyer-Lindenberg, A., Miletich, R.S., Kohn, P.D., Esposito, G., Carson, R.E., Quarantelli, M., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5 (2002), 267–271.
44. 44 McGowan, S., Lawrence, A.D., Sales, T., Quested, D., Grasby, P., Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61 (2004), 134–142.
45. 45 Lindstrom, L.H., Gefvert, O., Hagberg, G., Lundberg, T., Bergstrom, M., Hartvig, P., et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46 (1999), 681–688.
46. 46 Kumakura, Y., Cumming, P., Vernaleken, I., Buchholz, H.G., Siessmeier, T., Heinz, A., et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: An [18F]fluorodopa/positron emission tomography study. J Neurosci 27 (2007), 8080–8087.
47. 47 Nozaki, S., Kato, M., Takano, H., Ito, H., Takahashi, H., Arakawa, R., et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 108 (2009), 78–84.
48. 48 Elkashef, A.M., Doudet, D., Bryant, T., Cohen, R.M., Li, S.H., Wyatt, R.J., 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100 (2000), 1–11.
49. 49 Dao-Castellana, M.H., Paillere-Martinot, M.L., Hantraye, P., Attar-Levy, D., Remy, P., Crouzel, C., et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23 (1997), 167–174.
50. 50 Fusar-Poli, P., Meyer-Lindenberg, A., Striatal presynaptic dopamine in schizophrenia, part II: Meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull 39 (2013), 33–42.
51. 51 Howes, O.D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69 (2012), 776–786.
52. 52 Laruelle, M., Abi-Dargham, A., van Dyck, C.H., Gil, R., D'Souza, C.D., Erdos, J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93 (1996), 9235–9240.
53. 53 Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R.M., Seibyl, J.P., Bowers, M., et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 155 (1998), 761–767.
54. 54 Pogarell, O., Koch, W., Karch, S., Dehning, S., Muller, N., Tatsch, K., et al. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry 45:suppl 1 (2012), S36–S41.
55. 55 Breier, A., Su, T.P., Saunders, R., Carson, R.E., Kolachana, B.S., de Bartolomeis, A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94 (1997), 2569–2574.
56. 56 Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., Innis, R., Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 46 (1999), 56–72.
57. 57 Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000), 8104–8109.
58. 58 Abi-Dargham, A., van de Giessen, E., Slifstein, M., Kegeles, L.S., Laruelle, M., Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65 (2009), 1091–1093.
59. 59 Kegeles, L.S., Abi-Dargham, A., Frankle, W.G., Gil, R., Cooper, T.B., Slifstein, M., et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67 (2010), 231–239.
60. 60 Hitri, A., Casanova, M.F., Kleinman, J.E., Weinberger, D.R., Wyatt, R.J., Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biol Psychiatry 37 (1995), 175–182.
61. 61 Taylor, S.F., Koeppe, R.A., Tandon, R., Zubieta, J.K., Frey, K.A., In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 23 (2000), 667–675.
62. 62 Laakso, A., Vilkman, H., Alakare, B., Haaparanta, M., Bergman, J., Solin, O., et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 157 (2000), 269–271.
63. 63 Laruelle, M., Abi-Dargham, A., van Dyck, C., Gil, R., D'Souza, D.C., Krystal, J., et al. Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [(123)I]beta-CIT. Biol Psychiatry 47 (2000), 371–379.
64. 64 Laakso, A., Bergman, J., Haaparanta, M., Vilkman, H., Solin, O., Syvalahti, E., et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52 (2001), 115–120.
65. 65 Lavalaye, J., Linszen, D.H., Booij, J., Dingemans, P.M., Reneman, L., Habraken, J.B., et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 47 (2001), 59–67.
66. 66 Hsiao, M.C., Lin, K.J., Liu, C.Y., Tzen, K.Y., Yen, T.C., Dopamine transporter change in drug-naive schizophrenia: An imaging study with 99mTc-TRODAT-1. Schizophr Res 65 (2003), 39–46.
67. 67 Schmitt, G.J., la Fougere, C., Dresel, S., Frodl, T., Hahn, K., Moller, H.J., et al. Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naive schizophrenic patients. Schizophr Res 101 (2008), 133–141.
68. 68 Mateos, J.J., Lomena, F., Parellada, E., Mireia, F., Fernandez-Egea, E., Pavia, J., et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology 191 (2007), 805–811.
69. 69 Mateos, J.J., Lomena, F., Parellada, E., Font, M., Fernandez, E., Pavia, J., et al. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology 181 (2005), 401–406.
70. 70 Yoder, K.K., Hutchins, G.D., Morris, E.D., Brashear, A., Wang, C., Shekhar, A., Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 71 (2004), 371–375.
71. 71 Yang, Y.K., Yu, L., Yeh, T.L., Chiu, N.T., Chen, P.S., Lee, I.H., et al. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: A dual-isotope SPECT study. Am J Psychiatry 161 (2004), 1496–1498.
72. 72 Arakawa, R., Ichimiya, T., Ito, H., Takano, A., Okumura, M., Takahashi, H., et al. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: A positron emission tomography study of dopamine transporter. J Psychiatr Res 43 (2009), 1219–1223.
73. 73 Karlsson, P., Farde, L., Halldin, C., Sedvall, G., P.E.T. study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159 (2002), 761–767.
74. 74 Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22 (2002), 3708–3719.
75. 75 Abi-Dargham, A., Xu, X., Thompson, J.L., Gil, R., Kegeles, L.S., Urban, N., et al. Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: A PET study with [11C]NNC112. J Psychopharmacol 26 (2012), 794–805.
76. 76 Howes, O.D., Bose, S.K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L.R., et al. Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168 (2011), 1311–1317.
77. 77 Fusar-Poli, P., Howes, O.D., Allen, P., Broome, M., Valli, I., Asselin, M.C., et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 67 (2010), 683–691.
78. 78 Fusar-Poli, P., Howes, O.D., Allen, P., Broome, M., Valli, I., Asselin, M.C., et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16 (2011), 67–75.
79. 79 Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study. Mol Psychiatry 16 (2011), 885–886.
80. 80 Egerton, A., Chaddock, C.A., Winton-Brown, T.T., Bloomfield, M.A., Bhattacharyya, S., Allen, P., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort. Biol Psychiatry 74 (2013), 106–112.
81. 81 Demjaha, A., Murray, R.M., McGuire, P.K., Kapur, S., Howes, O.D., Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169 (2012), 1203–1210.
82. 82 Thompson, J.L., Urban, N., Slifstein, M., Xu, X., Kegeles, L.S., Girgis, R.R., et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 18 (2013), 909–915.
83. 83 Talvik, M., Nordstrom, A.L., Olsson, H., Halldin, C., Farde, L., Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: A PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6 (2003), 361–370.
84. 84 Suhara, T., Okubo, Y., Yasuno, F., Sudo, Y., Inoue, M., Ichimiya, T., et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59 (2002), 25–30.
85. 85 Glenthoj, B.Y., Mackeprang, T., Svarer, C., Rasmussen, H., Pinborg, L.H., Friberg, L., et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 60 (2006), 621–629.
86. 86 Kegeles, L.S., Slifstein, M., Xu, X., Urban, N., Thompson, J.L., Moadel, T., et al. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 68 (2010), 634–641.
87. 87 Kessler, R.M., Woodward, N.D., Riccardi, P., Li, R., Ansari, M.S., Anderson, S., et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65 (2009), 1024–1031.
88. 88 Kambeitz, J., Abi-Dargham, A., Kapur, S., Howes, O.D., Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: Systematic review and meta-analysis of imaging studies. Br J Psychiatry 204 (2014), 420–429.
89. 89 Kosaka, J., Takahashi, H., Ito, H., Takano, A., Fujimura, Y., Matsumoto, R., et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sci 86 (2010), 814–818.
90. 90 Poels, E.M., Girgis, R.R., Thompson, J.L., Slifstein, M., Abi-Dargham, A., In vivo binding of the dopamine-1 receptor PET tracers [11C]NNC112 and [11C]SCH23390: A comparison study in individuals with schizophrenia. Psychopharmacology 228 (2013), 167–174.
91. 91 Howes, O.D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P.K., et al. Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study. Brain 136 (2013), 3242–3251.
92. 92 Allen, P., Luigjes, J., Howes, O.D., Egerton, A., Hirao, K., Valli, I., et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull 38 (2012), 1268–1276.
93. 93 Zubieta, J.K., Taylor, S.F., Huguelet, P., Koeppe, R.A., Kilbourn, M.R., Frey, K.A., Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 49 (2001), 110–116.
94. 94 Lehrer, D.S., Christian, B.T., Kirbas, C., Chiang, M., Sidhu, S., Short, H., et al. 18F-fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophr Res 122 (2010), 43–52.
95. 95 Talvik, M., Nordstrom, A.L., Okubo, Y., Olsson, H., Borg, J., Halldin, C., et al. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148 (2006), 165–173.
96. 96 Tuppurainen, H., Kuikka, J.T., Laakso, M.P., Viinamaki, H., Husso, M., Tiihonen, J., Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256 (2006), 382–387.
97. 97 Graff-Guerrero, A., Mizrahi, R., Agid, O., Marcon, H., Barsoum, P., Rusjan, P., et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34 (2009), 1078–1086.
98. 98 Buchsbaum, M.S., Christian, B.T., Lehrer, D.S., Narayanan, T.K., Shi, B., Mantil, J., et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85 (2006), 232–244.
99. 99 Yasuno, F., Suhara, T., Okubo, Y., Sudo, Y., Inoue, M., Ichimiya, T., et al. Low dopamine D(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161 (2004), 1016–1022.
100. 100 Martinez, D., Slifstein, M., Broft, A., Mawlawi, O., Hwang, D.R., Huang, Y., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metabol 23 (2003), 285–300.
101. 101 Haber, S.N., Knutson, B., The reward circuit: Linking primate anatomy and human imaging. Neuropsychopharmacology 35 (2010), 4–26.
102. 102 Joel, D., Weiner, I., The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96 (2000), 451–474.
103. 103 Bentivoglio, M., Morelli, M., The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain. Handbook of Chemical Neuroanatomy 21 (2005), 1–107.
104. 104 Rice, M.E., Patel, J.C., Cragg, S.J., Dopamine release in the basal ganglia. Neuroscience 198 (2011), 112–137.
105. 105 Lammel, S., Hetzel, A., Hackel, O., Jones, I., Liss, B., Roeper, J., Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57 (2008), 760–773.
106. 106 Haber, S.N., Ryoo, H., Cox, C., Lu, W., Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: Comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 362 (1995), 400–410.
107. 107 Cropley, V.L., Innis, R.B., Nathan, P.J., Brown, A.K., Sangare, J.L., Lerner, A., et al. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse 62 (2008), 399–408.
108. 108 Kegeles, L.S., Slifstein, M., Frankle, W.G., Xu, X., Hackett, E., Bae, S.A., et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33 (2008), 3111–3125.
109. 109 Riccardi, P., Baldwin, R., Salomon, R., Anderson, S., Ansari, M.S., Li, R., et al. Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride. Biol Psychiatry 63 (2008), 241–244.
110. 110 Slifstein, M., Kegeles, L.S., Xu, X., Thompson, J.L., Urban, N., Castrillon, J., et al. Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 64 (2010), 350–362.
111. 111 Chuhma, N., Mingote, S., Moore, H., Rayport, S., Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 81 (2014), 901–912.
112. 112 Gonzales, K.K., Smith, Y., Cholinergic interneurons in the dorsal and ventral striatum: Anatomical and functional considerations in normal and diseased conditions. Ann N Y Acad Sci 1349 (2015), 1–45.
113. 113 Banghart, M.R., Neufeld, S.Q., Wong, N.C., Sabatini, B.L., Enkephalin disinhibits mu opioid receptor-rich striatal patches via delta opioid receptors. Neuron 88 (2015), 1227–1239.
114. 114 Brimblecombe, K.R., Cragg, S.J., Substance P weights striatal dopamine transmission differently within the striosome-matrix axis. J Neurosci 35 (2015), 9017–9023.
115. 115 Berger, B., Gaspar, P., Verney, C., Dopaminergic innervation of the cerebral cortex: Unexpected differences between rodents and primates. Trends Neurosci 14 (1991), 21–27.
116. 116 Tritsch, N.X., Sabatini, B.L., Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 76 (2012), 33–50.
117. 117 Schultz, W., Getting formal with dopamine and reward. Neuron 36 (2002), 241–263.
118. 118 Rice, M.W., Roberts, R.C., Melendez-Ferro, M., Perez-Costas, E., Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Struct Funct 221 (2016), 185–201.
119. 119 Akil, M., Edgar, C.L., Pierri, J.N., Casali, S., Lewis, D.A., Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47 (2000), 361–370.
120. 120 Mueller, H.T., Haroutunian, V., Davis, K.L., Meador-Woodruff, J.H., Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 121 (2004), 60–69.
121. 121 Ichinose, H., Ohye, T., Fujita, K., Pantucek, F., Lange, K., Riederer, P., et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm Park Dis Dement Sect 8 (1994), 149–158.
122. 122 Kemel, M.L., Desban, M., Glowinski, J., Gauchy, C., Distinct presynaptic control of dopamine release in striosomal and matrix areas of the cat caudate nucleus. Proc Natl Acad Sci U S A 86 (1989), 9006–9010.
123. 123 Graybiel, A.M., Ragsdale, C.W. Jr, Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc Natl Acad Sci U S A 75 (1978), 5723–5726.
124. 124 Perez-Costas, E., Melendez-Ferro, M., Roberts, R.C., Basal ganglia pathology in schizophrenia: Dopamine connections and anomalies. J Neurochem, 113, 2010, 287–302.
125. 125 Crittenden, JR., Graybiel, AM, Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat, 5, 2011, 59.
126. 126 Vernaleken, I., Buchholz, H.G., Kumakura, Y., Siessmeier, T., Stoeter, P., Bartenstein, P., et al. “Prefrontal” cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp 28 (2007), 931–939.
127. 127 Cools, R., Gibbs, S.E., Miyakawa, A., Jagust, W., D'Esposito, M., Working memory capacity predicts dopamine synthesis capacity in the human striatum. J Neurosci 28 (2008), 1208–1212.
128. 128 Cools, R., Frank, M.J., Gibbs, S.E., Miyakawa, A., Jagust, W., D'Esposito, M., Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. J Neurosci 29 (2009), 1538–1543.
129. 129 Deserno, L., Huys, Q.J., Boehme, R., Buchert, R., Heinze, H.J., Grace, A.A., et al. Ventral striatal dopamine reflects behavioral and neural signatures of model-based control during sequential decision making. Proc Natl Acad Sci U S A 112 (2015), 1595–1600.